Pfizer reported robust fourth-quarter 2024 earnings, exceeding expectations in both revenue and adjusted earnings.

Pfizer posted Q4 revenue of $17.76 billion, up 22% YoY, with strong sales from Paxlovid, Vyndaqel, and Eliquis. The company reaffirmed its 2025 revenue outlook.

When it comes to clip vs magazine, there seems to be some confusion among many shooters, or at least a tendency to say one when we mean to other. Both “clip” and “magazine” describe a ...

Pfizer PFE-0.49%decrease; red down pointing triangle has sold 700 million shares in British consumer-healthcare business Haleon HLN-0.95%decrease; red down pointing triangle for 2.50 billion ...

OneUp Components developed new Clip Pedals, and they are sure they might be your new favorite. OneUp says the new pedals are light enough for cross country but beefy and durable enough for downhill.

While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I think we did significant transformative changes in Pfizer.” ...

Pfizer saved $4 billion, plans $1.5 billion more in margin improvements, and issued $7 billion in dividends in nine months. Acquisitions are projected to offset $17 billion-18 billion in revenue ...

In the latest trading session, Pfizer (PFE) closed at $26.41, marking a -1.46% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.12%. At the same time ...

Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera Therapeutics outlining their plans in the space moving forward. At the 2025 ...

In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Pfizer (PFE – Research Report), with a price target of $33.00. Discover outperforming stocks and invest ...

Jan 13 (Reuters) - U.S. drugmaker Pfizer (PFE.N), opens new tab is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Executive ...

Pfizer CEO Dr Albert Bourla speaking at an event. Image Credit: Ververidis Vasilis / Shutterstock. Pfizer is cutting costs and refocussing its research and development (R&D) operations in a bid to ...